Startups
Edit
NanoBio
http://www.nanobio.com/Last activity: 16.01.2013
Active - Reference to BlueWillow Biologics
NanoBio Designs provides a highly efficient detection platform to verify the presence or absence and levels of targeted genetic markers in samples.
Our approach is to make simple self-service devices that detect based on DNA-coated nanoparticles rather than costly and complex Polymerase Chain Reactions (PCR).
Our initial platform, ExpresSeed, meets several of the unmet needs of hybrid seed producers seeking to track markers and those in food supply chains that need to validate genetic composition before purchase, sale, or export.
Our approach is to make simple self-service devices that detect based on DNA-coated nanoparticles rather than costly and complex Polymerase Chain Reactions (PCR).
Our initial platform, ExpresSeed, meets several of the unmet needs of hybrid seed producers seeking to track markers and those in food supply chains that need to validate genetic composition before purchase, sale, or export.
Overview
Location
United States, Michigan, Ann Arbor
Employees
11-50
Total raised
$23M
Founded date
2017
Funding Rounds 2
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
| Feb 18, 2009 | Funding round | $12M |
Mentions in press and media 13
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 29, 2012 | NanoBio Secures $11M Series C | ANN ARBOR, MI, NanoBio Corporation announced today the closing of an $11 million Series C financing, including full participation from its existing investor syndicate. >> Click here for more funding data on NanoBio >> To exp... |
| Nov 28, 2012 | NanoBio Closes $11M Series C Financing | NanoBio Corporation, an Ann Arbor, Michigan-based biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal & intramuscular vaccines derived from its patented N... |
| Nov 28, 2012 | NanoBio Corp. takes in another $11 million for emulsion-based topical drugs, intranasal vaccines | “Our topical therapeutic programs continue to show tremendous promise to enable new products that can effectively treat drug-resistant pathogens and avoid the concerning safety risks associated with oral therapies,” said CEO David Peralta i... |
| Dec 16, 2009 | Michigan’s NanoBio inks licensing agreement with GSK for cold-sore drug | Promoted This Patient Experience Checklist Is Your Key To Success in 2021 As healthcare systems strive to recover from losses due to the pandemic, patient acquisition and retention have never been more urgent, and patient experience has nev... |
| Jul 8, 2009 | NanoBio adds another $10 million to fund company through 2011 | Promoted Covid-19’s terrible toll on diabetes patients. What can be done? The public health crisis has undermined the economy and made people with chronic conditions more vulnerable and stressed. Learn more with a new report from Omada Heal... |
| Feb 18, 2009 | NanoBio raises $12 million to fund further clinical studies | John Coffey, NanoBio’s vice president for business development, said the company’s herpes labyalis treatment has the potential to be an over-the-counter treatment that is more effective than most prescription medications. The company also a... |
| Mar 7, 2008 | Life-science briefing: Friday, March 7, 2008 | TODAY’S HEADLINES: Allegro pulls in $4M for lung-cancer molecular diagnostics (release) Ocular bandage developer I-Therapeutix raises $6M (Mass High Tech) NanoBio gets last of $30M for skin-infection drugs (release) Cayenne Medical raises $... |
| NanoBio raises $12 million to fund further clinical studies | ANN ARBOR, Michigan — Michigan-based NanoBio Corp. said today that it raised $12 million, which it will use to complete Phase 1 studies on a topical treatment for acne, an inhalable mist for cystic fibrosis and an influenza vaccine delivere... | |
| NanoBio Corp. takes in another $11 million for emulsion-based topical drugs, intranasal vaccines | Anti-infection and dermatology drug company NanoBio Corp. raked in $11 million in series C financing from its existing lineup of investors, bringing its total to $130 million, half of which has come from nondilutive sources. With the fundin... |
Show more
Reviews 0
FAQ about NanoBio
When was NanoBio founded?
NanoBio was founded in 2017.
How much funding has NanoBio raised?
NanoBio has raised $23M in total across 2 funding rounds.
What funding rounds has NanoBio raised?
Parsers VC lists 2 funding rounds of NanoBio, among them a funding round of $12M on Feb 18, 2009.
What has the press written about NanoBio?
Parsers VC has collected 13 articles mentioning NanoBio, among them “NanoBio Secures $11M Series C” (Nov 29, 2012) and “NanoBio Closes $11M Series C Financing” (Nov 28, 2012).
Is NanoBio still active?
Yes, NanoBio is active; its latest activity on Parsers VC dates from Jan 16, 2013.